Insulin Lispro
Title: Insulin Lispro
CAS Registry Number: 133107-64-9
CAS Name: 28B-L-Lysine-29B-L-prolineinsulin (human)
Additional Names: [Lys(B28),Pro(B29)]-insulin (human)
Manufacturers' Codes: LY-275585
Trademarks: Humalog (Lilly)
Literature References: Rapid-acting insulin analog produced in E. coli by recombinant DNA technology. Identical to human insulin except for the transposition of proline and lysine at positions 28 and 29 on the B chain. Prepn: R. E. Chance et al., EP 383472; eidem, US 5514646 (1990, 1996 both to Lilly). Study of immunogenicity: C. M. Zwickl et al., Arzneim.-Forsch. 45, 524 (1995). General pharmacology: D. R. Helton et al., ibid. 46, 91 (1996). Clinical comparison with regular human insulin: J. H. Anderson, Jr. et al., Diabetes 46, 265 (1997). Review of development and pharmacokinetics: F. Holleman, J. B. L. Hoekstra, N. Engl. J. Med. 337, 176-183 (1997); of clinical trials: V. A. Koivisto, Ann. Med. 30, 260-266 (1998). Series of articles on pharmacology and clinical experience: Acta Clin. Belg. 54, 233-254 (1999).
Therap-Cat: Antidiabetic.
Keywords: Antidiabetic; Hormones/Analogs.

Others monographs:
Thallium OxidePhenethyl AlcoholMalondialdehydeFlurprimidol
αMNPPotassium Osmate(VI)Ammonium Tungstate(VI)Anatoxins
LeucomycinsPolythiazidePotassium TetroxalateN-Methylglucamine
©2016 DrugLead US FDA&EMEA